Our TechnologyHow It Works
Our innovative Topical Lingual / Neural Signaling platform enables the direct activation of specific brain regions responsible for metabolic regulation with natural peptide hormones delivered noninvasively with no side effects.*
The Catalent Zydis ODT dissolves on the tongue within 3 seconds, evenly dispersing the peptide in saliva. This groundbreaking approach ensures that the hormones do not enter the bloodstream, thereby avoiding any potential side effects.*
*No expected side effects, and no side effects seen in extensive toxicology, pre-clinical studies (most notably dogs and Asian musk shrews exhibit zero emesis) and successful Phase I (zero treatment-related adverse events).
A NOVEL APPROACH
Gila Therapeutics is the first and only company employing this novel tongue-brain connection for any indication. Placing a very small hormone dose on the tongue activates the brain’s satiety centers with no systemic exposure and no side effects.
Hormones bind to oral receptors resulting in rapid signaling to the brain. Direct neural connections deliver signals directly to the brainstem. Satiety centers in the brainstem and hypothalamus are stimulated without activating the nausea center.
Typically, therapeutic hormones are delivered systemically throughout the body. This requires greater amounts of hormone. And, because of this widespread distribution, other regions are exposed, including the brain’s nausea center.
The Alternative
The Obesity, Type 2 Diabetes, & Metabolic Disorder Crisis
Obesity not only exacerbates many other diseases, such as cardiovascular disease, type 2 diabetes, many types of cancer, and chronic liver and kidney diseases, but also significantly contributes to the healthcare costs in the U.S.
The obesity market is projected to reach a staggering $100 billion in 2030.
About 75% of the U.S. population is diagnosed with overweight, and more than 1/3 of the U.S. population is diagnosed with obesity.
OBESITY-RELATED PATIENT POPULATION
Obesity Epidemic
Worldwide:
1,100,000,000
United States:
115,196,430
Worldwide Metabolic Disorders
Type 2 Diabetes:
700,000,000
Cardiovascular Disease:
900,000,000
NASH:
400,000,000
NAFLD:
1,000,000,000
Chronic Kidney Disease:
1,100,000,000
Sources: 1. Center for Disease Control (CDC); 2. World Health Organization (WHO) 7.8bn people: 13% with obesity, 9% with diabetes.